Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment

Med Clin (Barc). 2024 Aug 30;163(4):208.e1-208.e10. doi: 10.1016/j.medcli.2024.02.006. Epub 2024 Apr 19.
[Article in English, Spanish]

Abstract

Migraine is a disease with a high prevalence and incidence, in addition to being highly disabling, causing a great impact on the patient's quality of life at a personal, family and work level, but also social, given its high expense due to its direct (care) and indirect (presenteeism and work absenteeism) costs. The multiple and recent developments in its pathophysiological knowledge and in its therapy require updating and, therefore, in this article the Spanish scientific societies most involved in its study and treatment (SEN, SEMFYC and SEMERGEN), together with the Association Spanish Association for Patients with Migraine and other Headaches (AEMICE), we have developed these updated care recommendations. We reviewed the treatment of migraine attacks, which consisted mainly of the use of NSAIDs and triptans, to which ditans and gepants have been added. We also discuss preventive treatment consisting of oral preventive drugs, botulinum toxin, and treatments that block the action of calcitonin-related peptide (CGRP). Finally, we emphasize that pharmacological treatments must be complementary to carrying out general measures consisting of identifying and managing/deletion the precipitating factors of the attacks and the chronicizing factors, controlling the comorbidities of migraine and eliminating analgesic overuse.

Keywords: CGRP; Lasmiditan; Lasmiditán; Migraine; Migraña; Onabotulinumtoxina; Toxina botulínica; Triptan; Triptán.

Publication types

  • Practice Guideline
  • Consensus Development Conference

MeSH terms

  • Analgesics / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal* / therapeutic use
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / therapy
  • Spain
  • Tryptamines* / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Tryptamines
  • Analgesics